A small supernumerary marker chromosome (sSMC) derived from chromosome 22 is a relatively common cytogenetic finding. This sSMC typically results in tetrasomy for a chromosomal region that spans the chromosome 22p arm and the proximal 2 Mb of 22q11.21. Using classical cytogenetics, fluorescence in situ hybridization, multiplex ligation-dependent probe amplification, and array techniques, 7 patients with sSMCs derived from chromosome 22 were studied: 4 non-related and 3 from the same family (mother, daughter, and son). The sSMCs in all patients were dicentric and bisatellited chromosomes with breakpoints in the chromosome 22 low-copy repeat A region, resulting in cat eye syndrome (CES) due to chromosome 22 partial tetrasomy 22pter→q11.2 including the cat eye chromosome region. Although all subjects presented the same chromosomal abnormality, they showed a wide range of phenotypic differences, even in the 3 patients from the same family. There are no previous reports of CES occurring within 3 patients in the same family. Thus, the clinical and follow-up data presented here contribute to a better delineation of the phenotypes and outcomes of CES patients and will be useful for genetic counseling.

1.
Allotey J, Lacaille F, Lees MM, Strautnieks S, Thompson RJ, Davenport M: Congenital bile duct anomalies (biliary atresia) and chromosome 22 aneuploidy. J Pediat Surg 43:1736–1740 (2008).
2.
Bartels I, Schlueter G, Liehr T, von Eggeling F, Starke H, et al: Supernumerary small marker chromosome (SMC) and uniparental disomy 22 in a child with confined placental mosaicism of trisomy 22: trisomy rescue due to marker chromosome formation. Cytogenet Genom Res 101:103–105 (2003).
3.
Bartsch O, Rasi S, Hoffmann K, Blin N: FISH of supernumerary marker chromosome (SMCs) identifies six diagnostically relevant intervals on chromosome 22q and a novel type of bisatellited SMC(22). Eur J Hum Genet 13:592–598 (2005).
4.
Belangero SI, Bellucco FT, Cernach MC, Hacker AM, Emanuel BS, Melaragno MI: Interrupted aortic arch type B in a patient with cat eye syndrome. Arq Bras Cardiol 92:e29–31 (2009).
5.
Berends MJ, Tan-Sindhunata G, Leegte B, van Essen AJ: Phenotypic variability of cat eye syndrome. Genet Counsel 12:23–34 (2001).
6.
Carter MT, St Pierre SA, Zackai EH, Emanuel BS, Boycott KM: Phenotypic delineation of Emanuel syndrome (supernumerary derivative 22 syndrome): clinical features of 63 individuals. Am J Med Genet A 149:1712–1721 (2009).
7.
Collingwood TN, Urnov FD, Wolffe AP: Nuclear receptors: coactivators, corepressors and chromatin remodeling in the control of transcription. J Mol Endocrinol 23:255–275 (1999).
8.
Coppinger J, McDonald-McGinn D, Zackai E, Shane K, Atkin JF, et al: Identification of familial and de novo microduplications of 22q11.21-q11.23 distal to 22q11.21 microdeletion syndrome region. Hum Mol Genet 18:1377–1383 (2009).
9.
Emanuel BS: Molecular mechanisms and diagnosis of chromosome 22q11.2 rearrangements. Dev Disabil Res Rev 14:11–18 (2008).
10.
Footz TK, Brinkman-Mills P, Banting GS, Maier SA, Riazi MA, et al: Analysis of the cat eye syndrome critical region in humans and the region of conserved synteny in mice: a search for candidate genes at or near the human chromosome 22 pericentromere. Genome Res 11:1053–1070 (2001).
11.
Jeanmougin F, Wurtz JM, Le Douarin B, Chambon P, Losson R: The bromodomain revisited. Trends Biochem Sci 22:151–153 (1997).
12.
Kulikowski LD, Yoshimoto M, da Silva Bellucco FT, Belangero SI, Christofolini DM, et al: Cytogenetic molecular delineation of a terminal 18q deletion suggesting neo-telomere formation. Eur J Med Genet 53:404–407 (2010).
13.
Liehr T: Small Supernumerary Marker Chromosomes (sSMC). (ed 1) (Springer-Verlag, Berlin 2012).
14.
Liehr T, Weise A: Frequency of small supernumerary marker chromosomes in prenatal, newborn, developmentally retarded and infertility diagnostics. Int J Mol Med 19:719–731 (2007).
15.
McTaggart KE, Budarf ML, Driscoll DA, Emanuel BS, Ferreira P, McDermid HE: Cat eye syndrome chromosome breakpoint clustering: identifications of two intervals also associated with 22q11 deletion syndrome breakpoint. Cytogenet Cell Genet 81:222–228 (1998).
16.
Mears AJ, Duncan AM, Budarf ML, Emanuel BS, Sellinger B, et al: Molecular characterization of the marker chromosome associated with cat eye syndrome. Am J Hum Genet 55:134–142 (1994).
17.
Nelle H, Schreyer I, Ewers E, Mrasek K, Kosyakova N, et al: Presence of harmless small supernumerary marker chromosomes hampers molecular genetic diagnosis: a case report. Mol Med Report 3:571–574 (2010).
18.
Riazi MA, Brinkman-Mills P, Nguyen T, Pan H, Phan S, et al: The human homolog of insect-derived growth factor, CECR1, is a candidate gene for features of cat eye syndrome. Genomics 64:277–285 (2000).
19.
Rosa RF, Mombach R, Zen PR, Graziadio C, Paskulin GA: Clinical characteristics of a sample of patients with cat eye syndrome. Rev Assoc Med Bras 56:462–466 (2010).
20.
Rosias PP, Sijstermans JM, Theunissen PM, Pulles-Heintzberger CF, de Die-Smulders CE, et al: Phenotypic variability of the cat eye syndrome. Case report and review if the literature. Genet Counsel 12:273–282 (2001).
21.
Schinzel A: Catalogue of Unbalanced Chromosome Aberrations in man, ed. 2 (De Gruyter, Berlin 2001).
22.
Winston F, Allis CD: The bromodomain: a chromatin-targeting module? Nat Struct Biol 6:601–604 (1999).
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.